

## Technical Data Sheet

### Human OX40 (C-His-Avi)

**Catalog Number:** 817801, 817802  
**Size:** 25 ug, 100 ug  
**Target Name:** TNFRSF4, OX40, CD134, OX40L receptor  
**Regulatory Status:** RUO

#### Product Details

---

**Application:** ELISA, BLI  
**Format:** Liquid, Purified  
**Expression Host:** CHO  
**Species:** Human  
**Sources:** Recombinant Human OX40 (Lue29-Ala216 ) with C-terminus His-Avi-tag is expressed in CHO cell.  
**Accession Number:** P43489  
**Molecular Weight:** The protein has a predicted molecular weight of 23.8 kDa. Under DTT-reducing conditions, it migrates at approximately 40 kDa on SDS-PAGE.  
**Affinity Tag:** C-His-Avi  
**Purity:** >95% based on SDS-PAGE under reducing condition  
**Formulation:** 1xPBS buffer, pH7.4, 0.22  $\mu$ m filtered  
**Endotoxin level:** Not tested  
**Protein Concentration:** 25 $\mu$ g size is bottled at 0.2mg/mL concentration. 100  $\mu$ g size is supplied at a lot-specific concentration.  
**Storage and Handling:** Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22  $\mu$ m-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at  $\leq -70^{\circ}\text{C}$  to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.


#### Background Information

---

OX40 (CD134) and its ligand OX40L (CD252), both part of the TNF receptor superfamily, play a key role in immune regulation. Their interaction is essential for T-cell expansion, survival, and cytokine production, influencing T cells, antigen-presenting cells, NK cells, and NKT cells. OX40-OX40L signaling helps break immune tolerance in malignancies, promoting antitumor immunity, and is also involved in the development of inflammatory and autoimmune diseases. Due to these regulatory effects, the OX40-OX40L pathway is a promising target for therapeutic interventions in both cancer and infectious diseases, with OX40 stimulation showing potential for therapeutic immunization strategies.

**Product Data**

---



Human OX40 (C-His-Avi) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95% based on reducing conditions.